Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMC

Endothelial senescent-cell-specific clearance alleviates metabolic dysfunction in obese mice

Suda M., Chaib S., Langhi Prata LGP., Zhu Y., Tripathi U., Paul KH.

Animal Study on Systemic / IV, published in Cell Metab (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Cell Metab (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41270738
PMCID
PMC12981281
DOI
10.1016/j.cmet.2025.10.009
Citations
10

Abstract (original English)

Accumulation of senescent cells is a key contributor to multiple diseases across the lifespan, including metabolic dysfunction. We previously demonstrated that elimination of senescent cells using senolytic drugs alleviates obesity-induced metabolic dysfunction. However, the contribution of senescent endothelial cells to metabolic disorders remains elusive. Hence, we crossed mice that allow selective elimination of senescent cells (p16 Ink4a -LOX-ATTAC mice) with Tie2-Cre mice (Tie2-Cre;p16 Ink4a -LOX-ATTAC) to enable identification and inducible, selective elimination of p16 Ink4a+ senescent endothelial cells. Targeted removal of senescent endothelial cells from obese Tie2-Cre;p16 Ink4a -LOX-ATTAC mice attenuated the pro-inflammatory senescence-associated secretory phenotype and alleviated metabolic dysfunction. Conversely, transplanting senescent endothelial cells into lean mice caused adipose tissue inflammation and metabolic dysfunction. Consistent with these findings, the senolytic, fisetin, which targets senescent endothelial cells among other senescent cell types, reduced adipose tissue senescent endothelial cell abundance and improved glucose metabolism in obese mice or mice transplanted with senescent mouse endothelial cells. Our results indicate that specifically eliminating p16 Ink4a+ senescent endothelial cells is a potential therapeutic strategy for metabolic disea

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueEndothelial CellsAnimalsMice, Inbred C57BLMiceMice, ObeseObesityFlavonoidsMaleCyclin-Dependent Kinase Inhibitor p16

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research